Deciding access to new Alzheimer's drugs; a wave of support for psychedelics among right-wing politicians

Taking stock of the drug industry, from the lab to the medicine chest

July 7, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe Opinion: We finally have new Alzheimer's drugs. How do we decide who gets them? If we're going to have better drugs like Leqembi to treat Alzheimer's, we need better, more accessible biomarkers to diagnose it, too. By Howard M. Fillit How the political right came to back psychedelics to treat trauma Bipartisan support is politically useful as states consider psychedelics-related policies and the FDA will soon weigh approving MDMA for PTSD. By Olivia Goldhill STAT+ | House panel expected to mark up pandemic-preparedness bill next week A House subcommittee will next week mark up a package of public health bills, including pandemic-preparedness legislation By John Wilkerson Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, transfers and promotions, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser